AP NEWS

Male Infertility - Pipeline Review, H2 2018: Featuring Cadila Healthcare and Health Ever Bio-Tech - ResearchAndMarkets.com

September 28, 2018

DUBLIN--(BUSINESS WIRE)--Sep 28, 2018--The “Male Infertility - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Male Infertility - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Male Infertility (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Infertility (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

This pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

Cadila Healthcare Ltd. Health Ever Bio-Tech Co. Ltd.

Key Topics Covered

1. Introduction

2. Report Coverage

3. Male Infertility - Overview

4. Male Infertility - Therapeutics Development

5. Pipeline Overview

6. Pipeline by Companies

7. Pipeline by Universities/Institutes

8. Products under Development by Companies

9. Products under Development by Universities/Institutes

10. Male Infertility - Therapeutics Assessment

11. Male Infertility - Companies Involved in Therapeutics Development

12. Male Infertility - Drug Profiles

13. Male Infertility - Dormant Projects

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rlctsj/male_infertility?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180928005363/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Sexual and Reproductive Health Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL CONSUMER MEN

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/28/2018 10:56 AM/DISC: 09/28/2018 10:56 AM

http://www.businesswire.com/news/home/20180928005363/en

AP RADIO
Update hourly